"Dutasteride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.
| Descriptor ID |
D000068538
|
| MeSH Number(s) |
D04.210.500.925.100.125
|
| Concept/Terms |
Dutasteride- Dutasteride
- 17beta-N-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one
|
Below are MeSH descriptors whose meaning is more general than "Dutasteride".
Below are MeSH descriptors whose meaning is more specific than "Dutasteride".
This graph shows the total number of publications written about "Dutasteride" by people in this website by year, and whether "Dutasteride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dutasteride" by people in Profiles.
-
Structure of human steroid 5a-reductase 2 with the anti-androgen drug finasteride. Nat Commun. 2020 10 27; 11(1):5430.
-
Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies. Curr Opin Urol. 2018 Jan; 28(1):42-45.
-
Effect of 5a-Reductase Inhibitor Use on Mortality From Prostate Cancer. JAMA Oncol. 2015 Jun; 1(3):321-2.
-
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015 Mar 15; 21(6):1273-80.
-
5a-reductase type 3 enzyme in benign and malignant prostate. Prostate. 2014 Feb; 74(3):235-49.
-
Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials. Cancer. 2013 Feb 01; 119(3):593-601.
-
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int. 2012 Apr; 109(8):1162-9.
-
The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol. 2011 Jan; 185(1):126-31.
-
Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 01; 362(13):1192-202.
-
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105.